{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:29:59Z","timestamp":1786969799719,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114147","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T01:56:47Z","timestamp":1717120607000},"page":"114147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer"],"prefix":"10.1016","volume":"207","author":[{"given":"Chengcong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Summer","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu Steven","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114147_bib1","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","article-title":"Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics","volume":"27","author":"Claret","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114147_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.114147_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","article-title":"Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development","volume":"86","author":"Wang","year":"2009","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.114147_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1158\/1078-0432.CCR-19-0287","article-title":"Progress and opportunities to advance clinical cancer therapeutics using tumor dynamic models","volume":"26","author":"Bruno","year":"2020","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.114147_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cpt.2953","article-title":"Early decision making in a randomized phase II trial of atezolizumab in biliary tract cancer using a tumor growth inhibition-survival modeling framework","volume":"114","author":"Shemesh","year":"2023","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.114147_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1208\/s12248-022-00710-4","article-title":"Tumor growth inhibition-overall survival (TGI-OS) model for subgroup analysis based on post-randomization factors: application for anti-drug antibody (ADA) subgroup analysis of atezolizumab in the IMpower150 study","volume":"24","author":"Yoshida","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.ejca.2024.114147_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/psp4.12629","article-title":"Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel","volume":"10","author":"Krishnan","year":"2021","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"10.1016\/j.ejca.2024.114147_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41467-023-36121-y","article-title":"Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.114147_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol: J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2024.114147_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1208\/s12248-020-0434-7","article-title":"Machine learning analysis of individual tumor lesions in four metastatic colorectal cancer clinical studies: linking tumor heterogeneity to overall survival","volume":"22","author":"Vera-Yunca","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.ejca.2024.114147_bib11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10928-020-09714-z","article-title":"Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment","volume":"47","author":"Mercier","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ejca.2024.114147_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100346","article-title":"Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy","volume":"7","author":"Kerioui","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114147_bib13","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.114147_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10585-015-9697-2","article-title":"Pattern of metastasis and outcome in patients with breast cancer","volume":"32","author":"Gerratana","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ejca.2024.114147_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bcp.12994","article-title":"Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer","volume":"82","author":"Zecchin","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2024.114147_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2024.114147_bib17","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/0008-5472.CAN-20-3665","article-title":"Spatiotemporal heterogeneity across metastases and organ-specific response informs drug efficacy and patient survival in colorectal cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.114147_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-018-3587-7","article-title":"Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study","volume":"82","author":"Claret","year":"2018","journal-title":"Cancer Chemother Pharm"},{"key":"10.1016\/j.ejca.2024.114147_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/psp4.12284","article-title":"Assessing similarity among individual tumor size lesion dynamics: the CICIL methodology","volume":"7","author":"Terranova","year":"2018","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"10.1016\/j.ejca.2024.114147_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13145","article-title":"Understanding of interaction (subgroup) analysis in clinical trials","volume":"49","author":"Brankovic","year":"2019","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.ejca.2024.114147_bib21","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bjc.2013.472","article-title":"Baseline tumour measurements predict survival in advanced non-small cell lung cancer","volume":"109","author":"Gerber","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114147_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114147_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:13Z","timestamp":1786969333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"alternative-id":["S0959804924008037"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114147","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114147"}}